Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.84 USD | +2.89% | +2.84% | -19.31% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.3B 1.77B |
---|---|---|---|---|---|
Net income 2024 * | -235M -320M | Net income 2025 * | -272M -371M | EV / Sales 2024 * | - |
Net cash position 2024 * | 725M 988M | Net cash position 2025 * | 476M 648M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.77
x | P/E ratio 2025 * |
-4.27
x | Employees | 59 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.99% |
Latest transcript on Akero Therapeutics, Inc.
1 day | +2.89% | ||
1 week | +2.84% | ||
Current month | +0.11% | ||
1 month | -6.18% | ||
3 months | -32.25% | ||
6 months | +6.68% | ||
Current year | -19.31% |
Managers | Title | Age | Since |
---|---|---|---|
Jonathan Young
FOU | Founder | 54 | 17-03-31 |
Timothy Rolph
FOU | Founder | 70 | 17-03-31 |
Andrew Cheng
CEO | Chief Executive Officer | 57 | 18-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Seth Harrison
BRD | Director/Board Member | 63 | 16-12-31 |
Jane Henderson
BRD | Director/Board Member | 58 | 19-04-22 |
Mark Iwicki
CHM | Chairman | 57 | 18-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.18% | 0 M€ | 0.00% | - | |
0.12% | 234 M€ | +8.48% | - | |
0.10% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 18.82 | +2.79% | 729,467 |
24-05-30 | 18.31 | -1.88% | 993,437 |
24-05-29 | 18.66 | -4.31% | 568,994 |
24-05-28 | 19.5 | +6.44% | 1,007,146 |
24-05-24 | 18.32 | -3.12% | 993,407 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.31% | 1.3B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- AKRO Stock